KIM, NAM-HOON,金楠勳,WANG, JIN SANG,王鎭相,KIM, BAEK KYUNG,金佰璟,JEON, BYEONGWOOK,田炳旭,LEE, BO RAM,李博蓝,李博藍,SON, MI KWON,孙美权,孫美權,CHOI, YEON SEO,崔然栖,崔然棲
申请号：
TW107144213
公开号：
TW201924721A
申请日:
2018.12.07
申请国别(地区):
TW
年份:
2019
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating lymphoma, containing a PI3 kinase inhibitor and a B-cell lymphoma 2 (Bcl-2) inhibitor, a method for treating lymphoma using the said composition, and a use of the said composition in preparing a drug for treating lymphoma. The PI3 kinase inhibitor according to the present invention is a compound represented by a Chemical Formula 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, wherein the said composition combines the PI3 kinase inhibitor and the Bcl-2 inhibitor, thus achieving an excellent effect on preventing and treating lymphoma due to a synergy effect resulting from such combination thereof.本發明係關於一種用來預防或治療淋巴瘤而包含有PI3激酶抑制劑以及Bcl-2抑制劑的醫藥組成物、將其用來治療淋巴瘤的方法，以及將其用以製備治療淋巴瘤醫藥組合物的用途。本發明的PI3激酶抑制劑係為化學式1所示的化合物、其立體異構物、其醫藥上可接受的鹽、其水合物，或其溶劑合物。所述組成物結合有PI3激酶抑制劑以及Bcl-2抑制劑，因兩者結合產生了增效作用（synergy effect），故而對於淋巴瘤的預防或治療具有極佳的效果。
